Fat Loss & Metabolic

Should You Take Foundayo or the Wegovy Pill?

Foundayo vs the Wegovy pill: weight loss, side effects, muscle loss, the 30-minute rule with thyroid tablets, Australian availability and blood tests.

Bruno SouzaBruno Souza20 Nov 202622 min readSupport My TRT
Share:
Should You Take Foundayo or the Wegovy Pill?

Two GLP-1 weight-loss pills were approved in Australia in the same month. The Wegovy pill (oral semaglutide, Novo Nordisk) was registered by the TGA on 3 November 2026. Foundayo (orforglipron, Eli Lilly) followed in the week of 16 November. Both are a tablet a day, both need a private script, and the headlines comparing them mostly stop at one number each.

The choice is more personal than that. One pill loses a little more weight on paper. The other is easier to live with and has no food rules. If you take thyroid medication in the morning, that difference matters more than the weight-loss gap. Below: what the trials showed, side effects and dropout, muscle loss, the 30-minute rule, what you can get right now, and the blood tests worth asking your GP for.

This article is educational, not medical advice. Both drugs are prescription-only. Talk to your GP before starting either, never change thyroid or other medication timing without your prescriber, and do not buy GLP-1 products outside the regulated supply chain.

Quick answer: There is no head-to-head trial in obesity. In separate trials the Wegovy pill (25mg) took off 13.6% of body weight at 64 weeks and Foundayo (top dose) 11.2% at 72 weeks, so the Wegovy pill probably edges it on weight. Foundayo is easier: take it any time, with or without food. The Wegovy pill must be taken on waking with no more than 120mL of plain water, then nothing to eat, drink or swallow for at least 30 minutes. If you take levothyroxine, that rule matters, and oral semaglutide raised thyroxine exposure by 33% in a drug interaction study, so ask for a TSH recheck 6 to 8 weeks after starting. Both pills are approved in Australia, neither is on the PBS, and neither had a published price as of 20 November 2026.

What can you actually get in Australia right now?

Both pills are approved. Neither was in pharmacies at the time of writing.

The Wegovy pill was approved by the TGA on 2 November 2026 and entered the register on 3 November, in 1.5mg, 4mg, 9mg and 25mg strengths (TGA, 2026). It is approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and to lower the risk of heart attack and stroke in people with established cardiovascular disease. Novo is aiming for launch before Christmas. There is no price yet; commentators expect something close to the injection, which launched at A$260 to A$460 a month (newsGP, 2024).

Foundayo was approved in the week of 16 November 2026 for adults with obesity, or overweight with a weight-related condition, and for type 2 diabetes (The Nightly, 2026). Lilly Australia said supply would follow within days. No Australian price yet. In the US both launched at the same self-pay starting price, US$149 a month for the lowest dose, with higher doses costing more (BioPharma Dive, 2026).

Neither pill is on the PBS. The PBAC has recommended subsidised Wegovy only for people with established cardiovascular disease and obesity, and nothing so far extends that to tablets or to Foundayo. Budget for the full private price.

Don't buy a "GLP-1 pill" online

Now that two real pills exist, the grey market will sell fake ones. The TGA has tested imported "GLP-1" products and found some contained no GLP-1 at all (TGA safety alert), and compounded GLP-1s have been banned in Australia since October 2024. A registered pill on a GP script is the only version you know is real.

Which pill loses more weight?

Wegovy pillFoundayo
CompanyNovo NordiskEli Lilly
DrugSemaglutide, a peptide, in a tablet with an absorption enhancerOrforglipron, a small non-peptide molecule
Main obesity trialOASIS 4, 307 people, 64 weeksATTAIN-1, 3,127 people, 72 weeks
Weight loss, everyone who started13.6% (placebo 2.2%)11.2% at top dose (placebo 2.1%)
Weight loss, people who stayed on it16.6%12.4%
How you take itOn waking, empty stomach, up to 120mL water, wait 30 minutesAny time, with or without food
Top dose25mg17.2mg tablet (36mg in trials)

The Wegovy pill result comes from OASIS 4 (Wharton et al., 2025a) and the Foundayo result from ATTAIN-1 (Wharton et al., 2025b). The trials differ in length and in who joined: OASIS 4 was mostly women and mostly White, while ATTAIN-1 was larger and far more diverse. You can't subtract one number from the other and call it a result.

The closest thing to a fair comparison is a Novo-funded analysis that adjusted for population differences and put the Wegovy pill about 3 percentage points ahead (Michalak et al., 2026). The confidence interval ran from 0.4 to 5.9 points, the share of people reaching 10%, 15% and 20% loss was not significantly different, and most of the authors are Novo employees. On the flip side, the same analysis found people were far more likely to quit Foundayo over side effects. Probably a real edge, probably small.

What about real-world results?

In mid-November Novo reported 6.2% average weight loss at three months in 5,872 people on the Wegovy pill through a US telehealth service, against 5.5% at 12 weeks in its trial (CTV News, 2026). People switching from injections lost 4.1% over the same three months (PharmExec, 2026). Both figures come from the company, are unreviewed, and only count people who kept taking it. Nothing equivalent has been published for Foundayo yet.

Which pill has fewer side effects?

Nausea, vomiting, diarrhoea and constipation are common on both. The difference is in how many people quit.

  • In OASIS 4, 74% of people on the Wegovy pill had a gut side effect versus 42% on placebo, but only 6.9% stopped because of side effects, against 5.9% on placebo (Wharton et al., 2025a).
  • In ATTAIN-1, 10.3% stopped Foundayo because of side effects on the top dose, against 2.7% on placebo (Wharton et al., 2025b).

The only true head-to-head, ACHIEVE-3, compared Foundayo with oral semaglutide in type 2 diabetes. Foundayo lowered HbA1c more (1.91 vs 1.47 points at top doses), but gut side effects hit 58% versus 45%, and about twice as many people quit (10% vs 5%) (Rosenstock et al., 2026). The semaglutide doses there were the 7mg and 14mg diabetes doses, not the 25mg Wegovy pill.

So Foundayo looks stronger on blood sugar in diabetes and rougher on the stomach. Slow titration helps with both: Foundayo starts at 0.8mg and the Wegovy pill at 1.5mg, each stepping up no faster than every 30 days.

What happens when you stop?

The weight comes back. After stopping injectable semaglutide, people regained about two thirds of what they had lost within a year (Wilding et al., 2022). Foundayo has one interesting role here. In ATTAIN-MAINTAIN, people who had lost weight on injections and switched to Foundayo kept 75% to 79% of the weight they had lost over a year, versus 38% to 49% on placebo (Aronne et al., 2026). If you are coming off an injection and want a pill to hold your result, that is the best evidence for either tablet.

How much muscle do you lose on each?

Some of the weight you lose on any GLP-1 is lean mass. The question is how much, and whether your choice of pill changes it.

For Foundayo, a 171-person DXA scan subgroup of ATTAIN-1 found that 73.1% of the weight lost was fat and 26.9% was lean mass. Lean mass fell 3.2% to 6.6% depending on dose, while placebo gained 0.3% (Eli Lilly Medical Information, 2026).

For the Wegovy pill, we could find no published body-composition data. The closest is the same molecule as a weekly injection. In the STEP 1 trial's DXA substudy of injectable semaglutide 2.4mg, close to 40% of the weight lost was lean mass (Wilding et al., 2021), and a 2026 meta-analysis of 20 trials put semaglutide at 35% (Eisa and Barood, 2026).

What that looks like for a 100kg person losing 11kg

Lean mass lostFat lost
Foundayo (26.9% lean)about 3.0kgabout 8.0kg
Semaglutide, meta-analysis (35%)about 3.9kgabout 7.1kg
Semaglutide, STEP 1 (about 40%)about 4.4kgabout 6.6kg
Diet alone (26%)about 2.9kgabout 8.1kg
Diet plus resistance training (17.5%)about 1.9kgabout 9.1kg

On paper Foundayo looks gentler on lean mass, by roughly a kilo. Don't read much into that. The trials and the people in them differ, and the same meta-analysis found lean mass loss on GLP-1s was proportionally no worse than dieting alone (Eisa and Barood, 2026). DXA "lean mass" also counts water, glycogen and organ tissue, not just muscle, and some of that loss is unavoidable when fat shrinks (Tinsley and Heymsfield, 2024).

What you do matters more than which pill you pick. In the same meta-analysis, adding resistance training cut lean mass to 17.5% of the weight lost. Higher-protein diets also preserve a bit more lean mass (Wycherley et al., 2012), and most GLP-1 users eat far too little protein because their appetite is gone. Aim for at least 1.2g to 1.6g of protein per kg of body weight a day and lift weights two or three times a week. If you're over 65, this is not optional.

For more on muscle loss across the newer drugs, see how much muscle you lose cutting on retatrutide and whether eloralintide protects muscle better than a GLP-1.

Enjoying this article?

Get evidence-based bloodwork guides delivered to your inbox every two weeks. No spam, unsubscribe anytime.

Free biweekly digest. No spam, unsubscribe anytime.

The 30-minute rule and your morning tablets

This is where the two pills really differ day to day.

Morning timeline: Wegovy pill at 6:00 with up to 120 mL water, nothing by mouth until 6:30, thyroid tablet and other medicines at 6:30, breakfast and coffee at 7:00. Foundayo: any time of day, with or without food.Click to expand

The Wegovy pill label is strict. Take it on an empty stomach in the morning with up to 120mL of plain water, swallow it whole, then wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medicines (Novo Nordisk, 2026). Coffee counts as a drink. So does a protein shake.

The reason is chemistry. Semaglutide is a peptide that would normally be digested, so the tablet carries an absorption enhancer (SNAC) that lets a small amount cross the stomach wall right next to the tablet (Buckley et al., 2018). Only about 0.8% of the dose gets absorbed under the recommended conditions, and more water or a shorter wait lowers that further (Overgaard et al., 2021). In the same trial, swallowing five other tablets alongside it cut semaglutide exposure by 34% (Hauge et al., 2021). Waiting longer than 30 minutes is fine and slightly improves absorption.

Foundayo has none of this. The label says once daily, with or without food (Eli Lilly, 2026), and food made almost no clinically relevant difference to absorption.

If you take levothyroxine (thyroxine)

Levothyroxine is one of the most prescribed medicines in Australia, and it has its own rule: empty stomach, usually 30 to 60 minutes before breakfast. Put that next to the Wegovy pill and you have two tablets that both want to go first, alone.

It gets more specific. In a drug interaction study, oral semaglutide raised total thyroxine exposure by 33% after a single levothyroxine dose (Hauge et al., 2021). That study used 45 healthy volunteers and the 14mg diabetes strength, not the 25mg Wegovy pill, and the two tablets were taken together. The study authors say thyroid levels should be monitored, and the Wegovy label calls for closer monitoring of narrow-margin drugs like this one. Nobody has tested whether spacing the tablets removes the effect.

Options to discuss with your prescriber:

  • Wegovy pill on waking, levothyroxine 30 minutes later, breakfast 30 to 60 minutes after that. This respects both labels, at the cost of a later breakfast.
  • Levothyroxine at bedtime instead. In a randomised crossover trial of 105 patients, bedtime dosing gave slightly better thyroid levels than morning dosing, with no difference in how people felt (Bolk et al., 2010). It separates the two drugs by hours.
  • Foundayo. With no fasting rule, levothyroxine stays where it is. There is no levothyroxine interaction data for it either way, though, and every GLP-1 slows stomach emptying, so the same recheck applies.

Whichever you pick, ask for TSH and free T4 about 6 to 8 weeks after starting and after any big dose change. Losing weight changes your levothyroxine needs too, so a moving TSH is not automatically the pill's fault.

Other things that don't fit the Wegovy pill window: calcium, iron and antacids (which also need to stay about 4 hours away from levothyroxine), morning supplements, pre-workout and coffee. If you train early and fasted, the wait plus breakfast timing can push your session back. Foundayo avoids all of it.

Foundayo's own interaction rules

Foundayo is cleared by the liver enzyme CYP3A4, so some medicines change its levels. Clarithromycin raised exposure 3.5-fold and caps the dose at 9mg; carbamazepine cut it by 82% and should be avoided (Eli Lilly, 2026). It also raises simvastatin levels, so simvastatin is capped at 20mg a day. If you use the oral contraceptive pill, the label says to add a barrier method or switch to a non-oral method for 30 days after starting Foundayo and for 30 days after each dose increase.

How to choose: a quick decision guide

  • You take levothyroxine or T3 in the morning and don't want to change it. Foundayo is simpler. If you prefer the Wegovy pill, plan the timing with your prescriber and book a TSH recheck.
  • You want the most weight loss from a pill and mornings are easy. The Wegovy pill has the stronger trial result, and the injection-equivalent dose.
  • You've had a heart attack, stroke or other established cardiovascular disease. The Wegovy pill is TGA-approved to reduce cardiovascular risk. Foundayo's approval has not been reported to include that.
  • You have type 2 diabetes. Foundayo lowered HbA1c more in the only head-to-head trial. Discuss hypoglycaemia risk if you also take insulin or a sulfonylurea.
  • You're coming off a GLP-1 injection. Foundayo has the maintenance trial behind it. The Wegovy pill is the same molecule as your injection.
  • You're on the oral contraceptive pill, clarithromycin, carbamazepine or HIV medicines. Check Foundayo's interaction rules first.
  • You struggle with nausea. The Wegovy pill had lower side-effect dropout in trials.
  • You want neither. Injections still lose more weight than either pill: tirzepatide took off about 21% at its top dose in its main trial (Jastreboff et al., 2022).

If you lift or are on TRT

A few things matter more if you train hard or use hormones.

Both drugs raise resting heart rate. The Foundayo label reports a mean rise of 4 to 5 bpm versus 0.5 on placebo; in ACHIEVE-3 it was 3.7 to 4.7 bpm on Foundayo against 1.0 to 1.5 bpm on oral semaglutide (Rosenstock et al., 2026). That stacks with anything else pushing your heart rate up: clenbuterol, T3, stimulant pre-workouts, trenbolone. Track your morning resting heart rate for the first two months of either pill.

Anything you swallow on waking has to wait 30 minutes behind the Wegovy pill, including oral anabolics like oxandrolone and aromatase inhibitors like anastrozole. Injected testosterone doesn't care about either pill.

A GLP-1 kills appetite, and protein is usually the first thing to drop. Hit 1.6g per kg a day and keep lifting heavy. On a cut for a show, either pill will make the last weeks easier on hunger. Neither will spare muscle for you.

TRT helps, but only while you're on it. In 100 obese men with low testosterone on a very low-calorie diet, testosterone injections led to 3.4kg less lean mass loss over a year than placebo (Ng Tang Fui et al., 2016). That was replacement-dose testosterone, not a GLP-1 trial, and the benefit had disappeared about 19 months (82 weeks) after stopping (Ng Tang Fui et al., 2017). Keep an eye on testosterone and haematocrit as usual.

Steroids already move liver enzymes, lipids and haematocrit. Get a baseline before you start the pill, or you won't know which drug moved what.

Support My TRT

Found this helpful? Keep the articles (and my TRT) going.

Buy Me a Coffee

Or donate crypto

BTCbc1qhd…u5gp
ETH0x12CE…C1e4

Send only the matching coin to each address. More ways to support

The blood tests to ask your GP for

Get a baseline before starting, then repeat at about 3 months and after reaching your maintenance dose.

  • Lipase and pancreatic amylase. Both rise on both drugs without symptoms. On Foundayo, lipase rose 26% to 31% and amylase 16% to 20% on average; the Wegovy label reports lipase up about 39% across semaglutide weight-loss trials. A raised number alone is not pancreatitis. Severe upper abdominal pain that goes through to your back is: stop the pill and get seen.
  • TSH and free T4 if you take thyroid medication, at 6 to 8 weeks.
  • ALT and AST. These usually fall as weight comes off. In pooled data from 11,220 people, liver enzymes fell on average on Foundayo and no case met the criteria for drug-induced liver injury (Wharton et al., 2026). The FDA still required Lilly to keep reporting and analysing liver cases after approval (FDA, 2026). That caution has history: an earlier small-molecule GLP-1 pill from Pfizer, lotiglipron, raised liver enzymes and was dropped (Amin et al., 2025).
  • Creatinine and eGFR. Vomiting and diarrhoea can dehydrate you enough to hurt the kidneys, especially during dose increases. If you're muscular, add cystatin C, because creatinine overestimates kidney trouble in people with more muscle.
  • HbA1c, fasting glucose and lipids (triglycerides, LDL, ApoB). These should improve, and that's the payoff worth seeing on paper.

For the full schedule on injectable GLP-1s, see GLP-1 bloodwork: what to test on semaglutide. For more on Foundayo, including its dose ladder and the history of its Australian approval, see our orforglipron Australia guide and the orforglipron vs semaglutide comparison.

Both pills carry the class warning about thyroid C-cell tumours from rodent studies and are not for anyone with a personal or family history of medullary thyroid cancer or MEN 2. Human data are mixed: a French study found a signal (Bezin et al., 2023), a much larger Scandinavian study did not (Pasternak et al., 2024). The absolute risk is very low either way.

See what your GLP-1 pill does to your bloodwork

Log your pill, dose steps and resting heart rate in VitalMetrics, upload your labs, and watch your thyroid, liver, pancreas, kidney and lipid markers on one timeline.

Try it Free

Key takeaways

  • Both pills are TGA-approved as of November 2026: the Wegovy pill on 3 November, Foundayo in the week of 16 November. Neither is on the PBS or had a published Australian price at the time of writing.
  • There is no head-to-head obesity trial. The Wegovy pill took off 13.6% at 64 weeks, Foundayo 11.2% at 72 weeks. A Novo-funded comparison puts the Wegovy pill about 3 points ahead.
  • Foundayo is easier to take: any time, with or without food. The Wegovy pill needs an empty stomach, up to 120mL of water, and a 30-minute wait before anything else.
  • More people quit Foundayo because of side effects (10.3% vs 6.9% in the main trials, and twice as many in the diabetes head-to-head).
  • On levothyroxine, oral semaglutide raised thyroxine exposure by 33%. Plan the timing with your prescriber and recheck TSH at 6 to 8 weeks.
  • Both raise resting heart rate, Foundayo more, and both raise lipase without symptoms. Get a baseline panel first.
  • Weight comes back after stopping either. Foundayo has the best evidence for holding weight after coming off injections.
Bruno Souza

Bruno Souza

IFBB competitor and founder of VitalMetrics. Passionate about harm reduction and helping athletes make informed decisions through bloodwork monitoring.

Found this helpful? Keep the articles (and my TRT) going.

Support My TRT

References

  1. Amin, N. B., Frederich, R., Tsamandouras, N., Haggag, A. Z., Schuster, T., et al. (2025). Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study. Diabetes, Obesity and Metabolism, 27(1), 215-227. PubMed
  2. Aronne, L. J., Horn, D. B., le Roux, C. W., Chao, A. M., Ho, W., Halpern, B., et al. (2026). Orforglipron for maintenance of body weight reduction: The double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine, 32(7), 2679-2687. PubMed
  3. Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J. L. (2023). GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care, 46(2), 384-390. PubMed
  4. Bolk, N., Visser, T. J., Nijman, J., Jongste, I. J., Tijssen, J. G., & Berghout, A. (2010). Effects of evening vs morning levothyroxine intake: A randomized double-blind crossover trial. Archives of Internal Medicine, 170(22), 1996-2003. PubMed
  5. Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. PubMed
  6. Eisa, N., & Barood, O. (2026). Lean mass changes with incretin therapy versus lifestyle intervention: A systematic review and meta-analysis of randomised controlled trials. Diabetes, Obesity and Metabolism, 28(6), 4818-4827. PubMed
  7. Eli Lilly and Company. (2026). Foundayo (orforglipron) tablets: Prescribing information. Link
  8. Eli Lilly and Company. (2026). What effect does Foundayo (orforglipron) have on body composition? Lilly Medical Information. Link
  9. Hauge, C., Breitschaft, A., Hartoft-Nielsen, M. L., Jensen, S., & Bækdal, T. A. (2021). Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects. Expert Opinion on Drug Metabolism & Toxicology, 17(9), 1139-1148. PubMed
  10. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. PubMed
  11. Michalak, W., Bøg, M., Bendixen, T., Chowdhury, R., Cowley, P., Laugesen, C., Rathor, N., & Kushner, R. F. (2026). Oral semaglutide 25 mg versus orforglipron 36 mg in obesity: A population-adjusted indirect treatment comparison. Diabetes, Obesity and Metabolism, 28(8), 7247-7256. PubMed
  12. Ng Tang Fui, M., Hoermann, R., Zajac, J. D., & Grossmann, M. (2017). The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment. Clinical Endocrinology, 87(4), 336-343. PubMed
  13. Ng Tang Fui, M., Prendergast, L. A., Dupuis, P., Raval, M., Strauss, B. J., Zajac, J. D., & Grossmann, M. (2016). Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: A randomised controlled trial. BMC Medicine, 14(1), 153. PubMed
  14. Novo Nordisk. (2026). Wegovy (semaglutide) injection and tablets: Prescribing information. DailyMed
  15. Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A., & Kildemoes, R. J. (2021). Clinical pharmacokinetics of oral semaglutide: Analyses of data from clinical pharmacology trials. Clinical Pharmacokinetics, 60(10), 1335-1348. PubMed
  16. Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., et al. (2024). Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ, 385, e078225. PubMed
  17. Rosenstock, J., Yabe, D., Cox, D., Li, J., Denning, M., Wu, W. S., Liu, R., & Zhao, Y. (2026). Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). The Lancet, 407(10534), 1147-1160. PubMed
  18. Therapeutic Goods Administration. (2026). Wegovy (semaglutide) tablets: Prescription medicine decision summary. Link
  19. Therapeutic Goods Administration. Imported unregistered GLP-1 weight loss products: Safety alert. Link
  20. Tinsley, G. M., & Heymsfield, S. B. (2024). Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. Journal of the Endocrine Society, 8(11), bvae164. PubMed
  21. U.S. Food and Drug Administration. (2026). Approval letter, NDA 220934 (Foundayo). Link
  22. Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., et al. (2025b). Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796-1806. PubMed
  23. Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., et al. (2025a). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393(11), 1077-1087. PubMed
  24. Wharton, S., Stefanski, A., Chen, J., Rao, G., Twum, E. A., & Denning, M. (2026). Hepatic safety of orforglipron in adults with obesity or overweight and/or type 2 diabetes: A pooled analysis of the orforglipron phase 3 clinical trials. Diabetes, Obesity and Metabolism, 28(9), 8347-8358. PubMed
  25. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. PubMed
  26. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. PubMed
  27. Wycherley, T. P., Moran, L. J., Clifton, P. M., Noakes, M., & Brinkworth, G. D. (2012). Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: A meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 96(6), 1281-1298. PubMed

More guides on the same markers and compounds.

Stay on top of your bloodwork

Get evidence-based articles on bloodwork, TRT, and harm reduction delivered to your inbox every two weeks.

Free biweekly digest. No spam, unsubscribe anytime.